Diarrhea

Cases of Cyclosporiasis on the Rise, CDC Warns

By August 08, 2017

A total of 206 cases of Cyclospora infections have been reported to the CDC as of August 2, 2017 among individuals who became ill on or after May 1, 2017.

Clinically Meaningful Reductions in HIV-Related Diarrhea with Long-Term Crofelemer

By July 27, 2017

Data from the analysis showed a 73% mean reduction in diarrhea episodes from baseline after treatment with Mytesi for 24 weeks.

CDC: Cryptosporidiosis Outbreaks Up at Aquatic Facilities

May 19, 2017

Ohio experienced a nearly 5-fold increase in cryptosporidiosis cases in 2016, with 1,940 reported cases compared with an average 399 cases during the prior 4 years.

First-in-Class Oral Enzyme Designated Breakthrough Therapy for CDI Prevention

By May 11, 2017

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for ribaxamase (SYN-004; Synthetic Biologics) for the prevention of Clostridium difficile infection (CDI).

How Common are Adverse GI Events with Statin Therapy?

By April 17, 2017

The analyses found no statistically significant difference between statin use and lower gastrointetinal conditions in constipation (OR 0.96, 95% CI: 0.87-1.05; P=0.33), abdominal pain (OR 0.95, 95% CI: 0.88-1.02; P=0.15), or colitis (OR 1.02, 95% CI: 0.91-1.14; P=0.73).

Xermelo Approved for Carcinoid Syndrome Diarrhea

By March 01, 2017

That FDA has approved Xermelo (telotristat ethyl) tablets as the first oral treatment for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

Drugs Often Overlooked as a Cause of Chronic Diarrhea

By February 09, 2017

Over 700 drugs have been associated with causing diarrhea.

Amneal Launches Generic Lotronex

By January 31, 2017

Amneal has launched Alosetron HCl Tablets, the generic equivalent to Prometheus' Lotronex.

<i>Clostridium difficile</i> Antibody Efficacy Examined in Real World Setting

January 26, 2017

Bezlotoxumab (Zinplava) is effective in reducing the risk of recurrent Clostridium difficile infection, according to research published in the New England Journal of Medicine.

Antidiarrheal May Be Increasing in Popularity as Drug of Abuse

By January 24, 2017

Clinicians should consider performing a screening electrocardiogram for patients who present after acute or chronic high-dose ingestion.

Is Bezlotoxumab Efficacy Affected by Concomitant Antibiotics for <i>C. diff</i>?

By October 27, 2016

Patients given bezlotoxumab exhibited significantly less Clostridium difficile infection (CDI) recurrence regardless of choice of standard of care (SoC) antibiotics, according to a study presented at IDWeek.

FDA Approves Zinplava to Prevent <i>C. diff</i> Infection Recurrence

By October 24, 2016

Zinplava is a human monoclonal IgG1/kappa antibody.

Mytesi Available to Treat Noninfectious Diarrhea in HIV Patients

By October 13, 2016

Crofelemer is a botanical drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest.

Antidepressant Efficacy Evaluated in Pediatric Abdominal Pain

By September 28, 2016

The review included children aged 5-21 years with functional abdominal pain treated with SSRI or TCA.

The Ins and Outs of Inulin, a Food with Function

September 20, 2016

Inulin exerts substantial prebiotic actions.

Oral Antibacterial Granted QIDP Status for C. Difficile-Associated Diarrhea

By September 12, 2016

The FDA has granted MGB-BP-3 (MGB Biopharma) Qualified Infectious Disease Product (QIDP) designation for the treatment of Clostridium difficile-associated diarrhea (CDAD).

New Warning, Administration Info Added to Labeling for OIC Drug Movantik

By August 24, 2016

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Movantik (naloxegol; AstraZeneca) tablets.

How Often is Fidaxomicin Used for <i>C. difficile</i> Infection?

By August 19, 2016

A slow but consistent increase in fidaxomicin use has been seen over time for the treatment of Clostridium difficile infection mostly in combination with other systemic antibiotics, study authors reported in Springer Plus.

Review: Management of Persistent Diarrhea

July 07, 2016

Microbiological causes of protracted diarrhea include detectable parasitic and bacterial pathogens

Zinplava Gets FDA Committee Nod for Prevention of CDI Recurrence

By June 10, 2016

Merck announced that the Antimicrobial Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 10-5 recommending the approval of Zinplava (bezlotoxumab) for the prevention of Clostridium difficile (C. difficile) infection recurrence.

FDA: Serious Heart Problems Possible with High Doses of Antidiarrheal

By June 07, 2016

The most severe cases involved doses ranging from 70mg-1600mg daily, which is 4-100 times the recommended dose.

Dangerous OTC Antidiarrheal Abuse on the Rise

By May 03, 2016

An increase in loperamide (Imodium) abuse as an opioid substitute has been seen among patients trying to self-treat their opioid addiction, according to a case studies report published in Annals of Emergency Medicine.

Reformulated Metronidazole Granted Orphan Drug for CDI in Children

By April 12, 2016

Appili Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for ATI-1501 (metronidazole) for the potential treatment of Clostridium difficile infection (CDI) in children.

Palatable CDI Tx for Children Designated Orphan Drug Status

By April 12, 2016

Appili Therapeutics announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation for ATI-1501 (metronidazole) for the potential treatment of Clostridium difficile infection (CDI) in children.

Updated Review Includes New C. diff Diagnosis, Treatment Guidance

By March 30, 2016

An update on the 2011 comparative effectiveness review on the early diagnosis, prevention, and treatment of Clostridium difficile was released to aid healthcare professionals, patients, policymakers, and others in well-informed decision-making.

Microbiome-Based Oral Drug Looks Promising for Recurrent C. difficile

By February 09, 2016

Positive results have been released from a Phase 1b/2 trial testing the efficacy of a microbiome-based, oral therapeutic drug to treat recurrent C. difficile infection.

Ani Launches Generic Vancocin

By November 23, 2015

Ani Pharmaceuticals announced the launch of Vancomycin HCl Capsules, the generic version of its Vancocin Capsules.

Microbiota Restoration Tx Designated Breakthrough Therapy for CDI

By October 13, 2015

The FDA has granted Breakthrough Therapy designation to RBX2660, a Microbiota Restoration Therapy (MRT), for the treatment of recurrent Clostridium difficile infection (CDI).

New Microbiome Therapy Granted Orphan Drug Designation for Recurrent CDI

By August 24, 2015

The Food and Drug Administration (FDA) has granted Orphan Drug designation to SER-109 (Seres Therapeutics) for the prevention of recurrent Clostridium difficile infection (CDI) in adults.

Pre-Referral Workup for GI, Liver Conditions Can Be Optimized

August 10, 2015

Pre-referral workup for gastroenterology and hepatology conditions can be optimized using Delphi methodology.